GALECTIN THERAPEUTICS INC. Line of Credit Facility, Maximum Borrowing Capacity
GALECTIN THERAPEUTICS INC. (GALT) had Line of Credit Facility, Maximum Borrowing Capacity of $10.00 million as of 2019-01-31, per its 10-K filed 2022-03-31.
Discontinued › Notes › Debt
us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity · last filed 2022-03-31
- 2019-01-31: Line of Credit Facility, Maximum Borrowing Capacity $10.00M.
| Period end | Line of Credit Facility, Maximum Borrowing Capacity |
|---|---|
| 2019-01-31 | $10.00M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |